Last reviewed 2026-04-20 · How we verify

Elrantamab (elrantamab)

Elrantamab, marketed by Pfizer, is a bispecific antibody targeting relapsed or refractory multiple myeloma, positioning it in a competitive landscape alongside Blinatumomab, Teclistamab, and Mosunetuzumab. Its key strength lies in its mechanism of action, which facilitates T-cell-mediated cytotoxicity against tumor cells, potentially offering enhanced efficacy. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics and biosimilars.

At a glance

Approved indications

• Relapsed or refractory multiple myeloma

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

• Bleeding risk may be increased with anticoagulants
• Bleeding risk may be increased with antiplatelet agents
• Bleeding risk may be increased with fibrinolytics
• Bleeding risk may be increased with heparin
• Bleeding risk may be increased with low molecular weight heparin
• Bleeding risk may be increased with thrombin inhibitors
• Bleeding risk may be increased with warfarin
• Avoid use of live vaccines
• Avoid use of live vaccines
• Avoid use of live vaccines
• Avoid use of live vaccines
• Avoid use of live vaccines

Key clinical trials

• Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Elrantamab CI brief — competitive landscape report
• Elrantamab updates RSS · CI watch RSS
• Pfizer portfolio CI